News: Portfolio 2008

CELLUMEN’S 2008 COLLABORATIONS VALIDATE NEW APPROACH TO IMPROVE DRUG SAFETY AND DEVELOPMENT

(continued)

identifying and eliminating compounds that result in toxic liabilities. Currently, this magnitude of cost savings is not realized by any other means.

 

Cellumen’s most recent collaborations include:

• Eli Lilly and Company (NYSE: LLY) – Collaborative partnership in which Lilly sends its new drug series compounds to Cellumen for evaluation through CellCiphr. Cellumen’s reports will prove invaluable as Lilly moves forward in developing pharmaceutical products that address major treatments in depression, schizophrenia, attention-deficit hyperactivity disorder, diabetes, osteoporosis and many other conditions.
• Mitsubishi Tanabe Pharma Corporation (4508:JP) – Agreement with MTPC, one of the leading pharmaceutical companies in Japan, to develop panels of biomarkers that identify toxicity early in the drug development process.

 

• National Center for Toxicology Research (NCTR) – Research collaboration with the NCTR, a research center of the Food and Drug Administration (FDA), to apply CellCiphr to profile blinded samples of known liver toxicity compounds including both failed and marketed drugs.
• Alzheimer’s Drug Discovery Foundation (ADDF) – Agreement with the ADDF to apply Cellumen’s CSB technology to create a cellular model of Alzheimer’s Disease that reveals the activity of multiple targets and pathways implicated in an intact, functioning cellular system.

 

“Conventional biochemical and high content screening toxicity assays simply do not have the statistical sensitivity required to help pharmaceutical companies prioritize their lead series among compounds that have more subtle toxic liabilities, and ultimately improve drug safety for consumers,” stated D. Lansing Taylor, PhD, CEO of Cellumen. “Our collaborations with some of the top pharmaceutical, governmental and research organizations in the world validate that Cellumen’s Cellular Systems Biology approach and CellCiphr toxicity assessment services have earned the confidence of the brightest minds in the healthcare industry as an

 

Page: 1 23